REZVOGLAR (insulin glargine-aglr)
REZVOGLAR is a long-acting human insulin analog indicated to improve glycemic control in both adult and pediatric patients with diabetes mellitus. It functions as a basal insulin to provide sustained regulation of blood sugar levels. This medication is not recommended for use in the treatment of diabetic ketoacidosis.
How REZVOGLAR Works
REZVOGLAR regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat while simultaneously inhibiting glucose production in the liver. These combined actions effectively lower blood glucose levels. Additionally, the drug inhibits the breakdown of fats and proteins and enhances the synthesis of new proteins.
Details
- Status
- Prescription
- First Approved
- 2021-12-17
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
REZVOGLAR Approval History
What REZVOGLAR Treats
2 indicationsREZVOGLAR is approved for 2 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Diabetes
- Diabetic Ketoacidosis
Pharmacists can substitute REZVOGLAR for Basaglar without calling the prescriber. This is a lower-cost alternative with no clinically meaningful differences.
REZVOGLAR Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in REZVOGLAR's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications REZVOGLAR treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to REZVOGLAR
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
REZVOGLAR FDA Label Details
Indications & Usage
FDA Label (PDF)REZVOGLAR is indicated for the treatment of Diabetes; Diabetic Ketoacidosis.
Track REZVOGLAR with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.